Vioxx Hearing Witnesses Push For Independent Drug Safety Office
This article was originally published in The Tan Sheet
Executive Summary
The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)